- Home
- RDI vs SCYX Comparison
RDI vs SCYX Comparison
Compare RDI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- SCYX
- Stock Information
- Founded
- RDI 1937
- SCYX 1999
- Country
- RDI United States
- SCYX United States
- Employees
- RDI N/A
- SCYX N/A
- Industry
- RDI Movies/Entertainment
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- SCYX Health Care
- Exchange
- RDI Nasdaq
- SCYX Nasdaq
- Market Cap
- RDI 27.9M
- SCYX 28.5M
- IPO Year
- RDI N/A
- SCYX 2014
- Fundamental
- Price
- RDI $1.34
- SCYX $0.76
- Analyst Decision
- RDI Hold
- SCYX
- Analyst Count
- RDI 1
- SCYX 0
- Target Price
- RDI $2.40
- SCYX N/A
- AVG Volume (30 Days)
- RDI 30.0K
- SCYX 178.0K
- Earning Date
- RDI 08-13-2025
- SCYX 08-07-2025
- Dividend Yield
- RDI N/A
- SCYX N/A
- EPS Growth
- RDI N/A
- SCYX N/A
- EPS
- RDI N/A
- SCYX N/A
- Revenue
- RDI $205,644,000.00
- SCYX $2,630,000.00
- Revenue This Year
- RDI $7.47
- SCYX $463.61
- Revenue Next Year
- RDI $13.22
- SCYX $310.80
- P/E Ratio
- RDI N/A
- SCYX N/A
- Revenue Growth
- RDI N/A
- SCYX N/A
- 52 Week Low
- RDI $1.17
- SCYX $0.66
- 52 Week High
- RDI $1.89
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- RDI 48.07
- SCYX 57.99
- Support Level
- RDI $1.24
- SCYX $0.67
- Resistance Level
- RDI $1.34
- SCYX $0.83
- Average True Range (ATR)
- RDI 0.06
- SCYX 0.04
- MACD
- RDI 0.00
- SCYX 0.02
- Stochastic Oscillator
- RDI 52.63
- SCYX 94.12
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.